The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study

Sponsor
University of Mississippi Medical Center (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02270164
Collaborator
Indena S.p.A (Industry)
0
1
2
16
0

Study Details

Study Description

Brief Summary

Pycrinil® is a purified extract of the artichoke leaf. Artichoke leaf extract (ALE) has some clinical trial data suggesting benefit in the treatment of cholesterol disorders in several countries, but this effect has not been studied in a U.S. population. The investigators will give ALE or a placebo to overweight men and women with low "good" cholesterol to see if ALE increases their good cholesterol. The investigators will also make sure that ALE is safe.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Artichoke Leaf Extract
  • Other: Placebo
N/A

Detailed Description

Subjects will be divided into one of two groups: (1) Pycrinil®/flaxseed oil or (2) Placebo/flaxseed oil twice daily with food. The two formulations will be identical in appearance and standardized by Indena, S.p.A. Patients will be enrolled for a total of 3 months (± 1 week to allow for scheduling flexibility) with a 1 month (± 1 week to allow for scheduling flexibility) first follow-up visit in between enrollment and final visits. At all visits, patients will be asked to monitor for any symptomatic ADE. The first follow-up visit will focus on medication compliance (via pill count) and safety assessment (including laboratories). The final study visit will consist of brief clinical assessment (including anthropometrics), completed lifestyle and physical activity assessments, subjective ADE reporting, and donated blood and urine for clinical laboratory tests. Medication changes are not prohibited during the study period, but must be recorded. Medication bottles will be collected at the first follow-up and final visits; pill counts will be performed to assess compliance.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Supportive Care
Official Title:
The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study
Study Start Date :
Oct 1, 2014
Actual Primary Completion Date :
Feb 1, 2016
Actual Study Completion Date :
Feb 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Artichoke Leaf Extract

Pycrinil® 100 mg/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food

Dietary Supplement: Artichoke Leaf Extract
Capsule
Other Names:
  • Pycrinil
  • Placebo Comparator: Placebo

    Placebo/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food

    Other: Placebo
    Capsule

    Outcome Measures

    Primary Outcome Measures

    1. Change in Concentrations of High Density Lipoprotein Cholesterol [3 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • ≥18 years of age

    • HDL cholesterol <40 mg/dL in men or <50 mg/dL in women

    • BMI ≥25 kg/m2.

    Exclusion Criteria:
    • Patient on statins

    • Triglycerides >400 mg/dL

    • Low density lipoprotein (LDL) >190 mg/dL

    • Significant hepatic disease (i.e., documented diagnosis of hepatic cancer, hepatitis, or cirrhosis)

    • Significant renal disease (i.e., most recent glomerular filtration rate <30 mL/min/1.73 m2)

    • Significant gastrointestinal tract disease (documented diagnosis of malabsorption disorder, GI cancer, or uncontrolled inflammatory bowel disease)

    • History of transplant

    • Women of reproductive potential not receiving birth control

    • Pregnant/nursing women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Mississippi Medical Center Jackson Mississippi United States 39216

    Sponsors and Collaborators

    • University of Mississippi Medical Center
    • Indena S.p.A

    Investigators

    • Principal Investigator: Daniel M Riche, PharmD, University of Mississippi Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Daniel Riche, Associate Professor, University of Mississippi Medical Center
    ClinicalTrials.gov Identifier:
    NCT02270164
    Other Study ID Numbers:
    • 2014-0167
    First Posted:
    Oct 21, 2014
    Last Update Posted:
    May 19, 2016
    Last Verified:
    May 1, 2016
    Keywords provided by Daniel Riche, Associate Professor, University of Mississippi Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 19, 2016